-
Je něco špatně v tomto záznamu ?
Single centre clinical experience with fidaxomicin in the treatment of Clostridium difficile infection in Slovakia
M. Novotný, P. Jarčuška, L. Gombošová, J. Hockicko, I. Hockicková, A. Rovňáková, O. Zahornacký, I. Schréter, E. Dorko, K. Rimárová
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
Digitální knihovna NLK
Zdroj
NLK
Free Medical Journals
od 2004
ProQuest Central
od 2009-03-01 do Před 6 měsíci
Medline Complete (EBSCOhost)
od 2006-03-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest)
od 2009-03-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 2009-03-01 do Před 6 měsíci
Public Health Database (ProQuest)
od 2009-03-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources
od 1993
PubMed
30817879
DOI
10.21101/cejph.a5476
Knihovny.cz E-zdroje
- MeSH
- antibakteriální látky terapeutické užití MeSH
- Clostridioides difficile účinky léků izolace a purifikace MeSH
- dítě MeSH
- dospělí MeSH
- fidaxomicin terapeutické užití MeSH
- klostridiové infekce diagnóza farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Slovenská republika MeSH
OBJECTIVE: Clostridium difficile infection (CDI) has become one of the most common causes of hospital-acquired infections. Fidaxomicin is one of the latest antibiotics used in the treatment of CDI, however, treatment cost affects recommendations for its use in several countries. We have analysed the treatment of our patients with CDI, treated by fidaxomicin since it was introduced to the market in 2018 and became available in the second biggest Slovak hospital, University Hospital of L. Pasteur. Our aim was to determine efficacy and safety of fidaxomicin in the treatment of CDI in Slovak patients. METHODS: We reviewed all courses of fidaxomicin use in our hospital (n = 60). Fidaxomicin was used for first recurrence (12 times), second recurrence (4 times), third recurrence (2 times), and fifth recurrence (1 patient). 41 patients received fidaxomicin first-line. RESULTS: Success of fidaxomicin treatment was recorded at 86.7% within the whole cohort. In the recurrent Clostridium difficile infection (rCDI) subgroup, fidaxomicin was 63% effective with three patients dying (15.7%) and two patients developing subsequent rCDI. During the duration of the study, 6 patients in total died. Only one of three patients, with three or more recurrences of CDI, had no further presentations after eight weeks of completion of treatment. CONCLUSIONS: The biggest benefit from fidaxomicin treatment was shown in a cohort of patients with primary CDI infection demonstrating a low recurrence rate and significant reduction of fidaxomicin effectiveness in preventing a recurrence when treating patients with multiple rCDI.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19039797
- 003
- CZ-PrNML
- 005
- 20201116143738.0
- 007
- ta
- 008
- 191112s2018 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21101/cejph.a5476 $2 doi
- 035 __
- $a (PubMed)30817879
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Novotný, Martin $7 xx0241938 $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice and Louis Pasteur University Hospital, Kosice, Slovak Republic
- 245 10
- $a Single centre clinical experience with fidaxomicin in the treatment of Clostridium difficile infection in Slovakia / $c M. Novotný, P. Jarčuška, L. Gombošová, J. Hockicko, I. Hockicková, A. Rovňáková, O. Zahornacký, I. Schréter, E. Dorko, K. Rimárová
- 520 9_
- $a OBJECTIVE: Clostridium difficile infection (CDI) has become one of the most common causes of hospital-acquired infections. Fidaxomicin is one of the latest antibiotics used in the treatment of CDI, however, treatment cost affects recommendations for its use in several countries. We have analysed the treatment of our patients with CDI, treated by fidaxomicin since it was introduced to the market in 2018 and became available in the second biggest Slovak hospital, University Hospital of L. Pasteur. Our aim was to determine efficacy and safety of fidaxomicin in the treatment of CDI in Slovak patients. METHODS: We reviewed all courses of fidaxomicin use in our hospital (n = 60). Fidaxomicin was used for first recurrence (12 times), second recurrence (4 times), third recurrence (2 times), and fifth recurrence (1 patient). 41 patients received fidaxomicin first-line. RESULTS: Success of fidaxomicin treatment was recorded at 86.7% within the whole cohort. In the recurrent Clostridium difficile infection (rCDI) subgroup, fidaxomicin was 63% effective with three patients dying (15.7%) and two patients developing subsequent rCDI. During the duration of the study, 6 patients in total died. Only one of three patients, with three or more recurrences of CDI, had no further presentations after eight weeks of completion of treatment. CONCLUSIONS: The biggest benefit from fidaxomicin treatment was shown in a cohort of patients with primary CDI infection demonstrating a low recurrence rate and significant reduction of fidaxomicin effectiveness in preventing a recurrence when treating patients with multiple rCDI.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antibakteriální látky $x terapeutické užití $7 D000900
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a klostridiové infekce $x diagnóza $x farmakoterapie $7 D003015
- 650 _2
- $a Clostridioides difficile $x účinky léků $x izolace a purifikace $7 D016360
- 650 _2
- $a fidaxomicin $x terapeutické užití $7 D000077732
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Slovenská republika $x epidemiologie $7 D018154
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jarčuška, Pavol $7 xx0073933 $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice and Louis Pasteur University Hospital, Kosice, Slovak Republic
- 700 1_
- $a Gombošová, Laura, $d 1967- $7 xx0229169 $u 1st Department of Internal Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice and Louis Pasteur University Hospital, Kosice, Slovak Republic
- 700 1_
- $a Hockicko, Ján $7 xx0241916 $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice and Louis Pasteur University Hospital, Kosice, Slovak Republic
- 700 1_
- $a Hockicková, Ivana $7 xx0241104 $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice and Louis Pasteur University Hospital, Kosice, Slovak Republic
- 700 1_
- $a Rovňáková, Alena $7 xx0241883 $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice and Louis Pasteur University Hospital, Kosice, Slovak Republic
- 700 1_
- $a Zahornacký, Ondrej $7 xx0241911 $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice and Louis Pasteur University Hospital, Kosice, Slovak Republic
- 700 1_
- $a Schréter, Ivan $7 xx0128894 $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice and Louis Pasteur University Hospital, Kosice, Slovak Republic
- 700 1_
- $a Dorko, Erik $7 xx0063738 $u Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic
- 700 1_
- $a Rimárová, Kvetoslava, $d 1958- $7 xx0224806 $u Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic
- 773 0_
- $w MED00001083 $t Central European journal of public health. Trends in Communicable and Non-communicable Diseases in Eastern Slovakia $x 1210-7778 $g Roč. 26, Suppl. (2018), s. S76-S80
- 773 0_
- $t Trends in communicable and non-communicable diseases in Eastern Slovakia $g (2018), s. S76-S80 $w MED00204324
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30817879 $y Pubmed
- 910 __
- $a ABA008 $b B 1829 $c 562 $y p $z 0
- 990 __
- $a 20191112 $b ABA008
- 991 __
- $a 20201116143737 $b ABA008
- 999 __
- $a ok $b bmc $g 1464358 $s 1078392
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 26 $c Suppl. $d S76-S80 $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $o Trends in Communicable and Non-communicable Diseases in Eastern Slovakia $x MED00001083
- BMC __
- $a 2018 $d S76-S80 $m Trends in communicable and non-communicable diseases in Eastern Slovakia $x MED00204324
- LZP __
- $b NLK118 $a Pubmed-20191112
